122 related articles for article (PubMed ID: 2144515)
1. Antitumor activity and pharmacokinetics of a morpholino-anthracycline derivative (KRN8602) against human breast carcinoma xenografts serially transplanted into nude mice.
Kubota T; Suto A; Josui K; Ishibiki K; Abe O; Yamada Y; Asanuma F; Kawamura E; Koh J; Shiina E
Jpn J Cancer Res; 1990 Aug; 81(8):827-33. PubMed ID: 2144515
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacokinetics of KRN8602, a new morpholino anthracycline, and adriamycin in tumor-bearing mice.
Shinkai H; Takahashi H; Miyamoto K; Uchida T; Tokiwa T
Cancer Chemother Pharmacol; 1996; 38(5):417-24. PubMed ID: 8765434
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of KRN8602, 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin hydrochloride, MX2 x HCl in patients with metastatic breast cancer.
Katsumata N; Watanabe T; Tominaga T; Ogawa M; Adachi I; Enomoto K; Kajiwara T; Kusama M; Yamada Y; Abe O
Cancer Chemother Pharmacol; 1999; 43(6):441-4. PubMed ID: 10321502
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancer.
Clarke K; Basser RL; Maher D; Morgan DJ; Cebon J; Fox RM; Hill JS; Alt C; Bartlett J; Geldard H; Kaye AH; Green MD
J Clin Oncol; 1998 Jun; 16(6):2181-7. PubMed ID: 9626219
[TBL] [Abstract][Full Text] [Related]
5. MX2; 3'-deamino-3'-morpholino-13-deoxy-10-hydroxycarminomycin (KRN8602) in refractory metastatic breast cancer: results of a preliminary phase II trial.
Watanabe T; Narabayashi M; Haga S; Yamada Y; Kawamura E; Enomoto K; Kusama M; Kimura K; Adachi I; Abe O
Jpn J Clin Oncol; 1993 Aug; 23(4):246-9. PubMed ID: 8411738
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of pre-irradiation KRN8602 (MX2) in malignant glioma patients.
Kuratsu JI; Arita N; Kayama T; Kubo N; Mori T; Sawamura Y; Ushio Y
J Neurooncol; 2000 Jun; 48(2):145-9. PubMed ID: 11083079
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of KRN8602(MX2), a novel morpholino anthracycline derivative, in patients with recurrent malignant glioma.
Kuratsu J; Arita N; Kurisu K; Uozumi T; Hayakawa T; Ushio Y
J Neurooncol; 1999 Apr; 42(2):177-81. PubMed ID: 10421076
[TBL] [Abstract][Full Text] [Related]
8. [Phase I and pharmacokinetic study of KRN8602, a new morpholino anthracycline].
Tabata M; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nagamine D; Shinagawa K; Fukutani H; Hirano A; Mizunuma N
Gan To Kagaku Ryoho; 1989 Jul; 16(7):2361-6. PubMed ID: 2546503
[TBL] [Abstract][Full Text] [Related]
9. [Phase II study of KRN8602 (MX2) for malignant lymphoma].
Okabe K; Sampi K; Kuraishi Y; Takemoto Y; Tamura K; Ogawa M
Gan To Kagaku Ryoho; 1998 Jun; 25(7):1001-6. PubMed ID: 9644314
[TBL] [Abstract][Full Text] [Related]
10. Comparison of antitumor activity of new anthracycline analogues, ME2303, KRN8602, and SM5887 using human lung cancer cell lines.
Takigawa N; Ohnoshi T; Ueoka H; Kiura K; Kimura I
Acta Med Okayama; 1992 Aug; 46(4):249-56. PubMed ID: 1442149
[TBL] [Abstract][Full Text] [Related]
11. A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
Takemoto Y; Sampi K; Kuraishi Y; Okabe K; Tamura K; Mizoguchi H; Saito H; Masaoka T; Ogawa M
Int J Hematol; 1999 Jul; 70(1):20-5. PubMed ID: 10446490
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetics and antitumor activity of MX2, a new morpholino anthracycline in brain tumor intracerebral transplanted in rats].
Kiya K; Ogasawara H; Fujita H; Sugiyama K; Kurisu K; Kawamoto K; Uozumi T; Shinkai H
Gan To Kagaku Ryoho; 1993 Apr; 20(5):631-5. PubMed ID: 8470921
[TBL] [Abstract][Full Text] [Related]
13. [Early phase II study of KRN8602 (MX2), a novel anthracycline derivative for acute leukemia].
Takemoto Y; Sampi K; Kuraishi Y; Toki H; Tamura K; Ogawa M
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2243-8. PubMed ID: 9881081
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice.
Kubota T; Matsuzaki SW; Hoshiya Y; Watanabe M; Kitajima M; Asanuma F; Yamada Y; Koh JI
J Surg Oncol; 1997 Feb; 64(2):115-21. PubMed ID: 9047247
[TBL] [Abstract][Full Text] [Related]
15. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
Watanabe M; Komeshima N; Nakajima S; Tsuruo T
Cancer Res; 1988 Dec; 48(23):6653-7. PubMed ID: 3180075
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activities of KW-2152, a new isoquinon agent, against human tumor xenografts transplanted into nude mice.
Nosoh Y; Nishiyama M; Niimi K; Hirabayashi N; Toge T; Niimoto M; Hattori T
Jpn J Surg; 1987 Mar; 17(2):146-9. PubMed ID: 3626206
[TBL] [Abstract][Full Text] [Related]
17. [Antitumor effect of a new anthracycline derivative, MX2, against human glioma cells].
Kuratsu J; Mihara Y; Kochi M; Takaki S; Ushio Y
Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):399-403. PubMed ID: 2930204
[TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
[TBL] [Abstract][Full Text] [Related]
19. In vivo antitumor activity of hexamethylmelamine against human breast, stomach and colon carcinoma xenografts.
Tanino H; Kubota T; Yamada Y; Koh J; Kase S; Furukawa T; Kuo TH; Saikawa Y; Kitajima M; Naito Y
Jpn J Cancer Res; 1995 Aug; 86(8):770-5. PubMed ID: 7559101
[TBL] [Abstract][Full Text] [Related]
20. Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models.
Burade V; Bhowmick S; Maiti K; Zalawadia R; Ruan H; Thennati R
BMC Cancer; 2017 Jun; 17(1):405. PubMed ID: 28587612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
